Breeze Meds vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Breeze Meds scores higher on our rubric, 7.3/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit MEDVi - $179 first month, then $299/mo →or find your match

Breeze Meds beats MEDVi overall, scoring 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Breeze Meds is from $199/mo; MEDVi is $179 first month, then $299/mo. Choose Breeze Meds for users who want to order compounded glp-1s month-by-month with no subscription commitment. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.

A side-by-side look at Breeze Meds and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

Breeze Meds

#29 of 54

7.3/10

Compounded GLP-1 provider focused on fast shipping and a no-fuss enrollment process.

Visit Breeze Meds

MEDVi

#46 of 54

5.7/10

MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.

Visit MEDVi

Feature	Breeze Meds	MEDVi
Why each one	No subscription required, pay per order rather than committing to recurring billing, with three formulation options including oral tablets.	Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.
Our Score	7.3/10	5.7/10
Headline Price	from $199/mo	$179 first month, then $299/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Users who want to order compounded GLP-1s month-by-month with no subscription commitment	Users who want both oral and injectable compounded options in one telehealth program
Watch out for	Independent reviews are very limited and the company structure is unclear, so legitimacy is hard to verify. Ask for pharmacy details first; the no-subscription model at least keeps a first order low-commitment.	FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
Ranking	#29	#46
Get started	Visit Breeze Meds	Visit MEDVi

Pros & Cons Compared

Breeze Meds

Pros

+No subscription required, order on demand without recurring billing commitments
+Three formulation options: injectable semaglutide, oral semaglutide tablet, and oral tirzepatide tablet
+FSA/HSA eligible for those with health savings accounts
+Discreet packaging on all shipments

Cons

−Independent reviews are very limited and the company structure is unclear, so legitimacy is hard to verify. Ask for pharmacy details first; the no-subscription model at least keeps a first order low-commitment.
−Oral options at $299-399/mo cost significantly more than injectable alternatives. The $199 injectable semaglutide is the value pick unless tablets are a must.
−Not available in all 50 states; availability depends on provider licensure, so check your state early in the online visit.

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping

Cons

−FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
−Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
−The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
−Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Our Verdict

Breeze Meds edges out MEDVi with a score of 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Breeze Meds is from $199/mo; MEDVi is $179 first month, then $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility.